Compare HP Inc (HPQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Recursion Pharmaceuticals Inc — how do they compare? HP Inc trades at $32.32 (market cap $29.25B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: HP Inc is far larger — about 13.7× Recursion Pharmaceuticals Inc's market cap, and HP Inc pays a 3.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HPQ | RXRX | |
|---|---|---|
Market Cap | $29.25B | $2.14B |
Volume | 10,025,806 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $35.48 | $6.79 |
52-Week Low | $18.20 | $2.84 |
Typical Hold Time | 70 Days | 22 Days |
Enterprise Value | $35.42B | $1.66B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.24, up 1.61% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, maintaining stable revenue around $55B with a 4.14% net margin. Recent news highlights HP's new PC launches and AI capabilities, though the stock faces headwinds from a projected mid-single-digit PC market decline in 2027.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38 and P/S of 0.51, and strong cash flow supports dividends. However, negative shareholder equity and competitive pressures in the PC market present risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
